Table 2.
Immunohistochemical MQSs (0–8) for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive ductal cancer and ductal carcinoma in situ
| Protein | Cancer type | Location | Tumour no. (%) | MQS 0–2 (0) | MQS 3–5 (1+) | MQS 6–8 (2+) |
| p14ARF | Invasive | Nucleus | 96 | 20 (21) | 31 (32) | 45 (47) |
| Cytoplasm | 95 | 72 (76) | 16 (17) | 7 (7) | ||
| DCIS | Nucleus | 91 | 17 (17) | 29 (32) | 45 (49) | |
| Cytoplasm | 91 | 70 (80) | 13 (14) | 8 (9) | ||
| p53 | Invasive | Nucleus | 93 | 62 (67) | 17 (18) | 14 (15) |
| Cytoplasm | 93 | 70 (75) | 18 (19) | 5 (5) | ||
| DCIS | Nucleus | 91 | 66 (73) | 12 (13) | 13 (14) | |
| Cytoplasm | 91 | 58 (62) | 27 (29) | 6 (6) | ||
| Hdm2 | Invasive | Nucleus | 92 | 49 (53) | 33 (36) | 10 (11) |
| Cytoplasm | 91 | 42 (46) | 33 (36) | 16 (18) | ||
| DCIS | Nucleus | 91 | 51 (56) | 25 (27) | 15 (16) | |
| Cytoplasm | 91 | 43 (47) | 27 (30) | 21 (23) |
Tumour numbers scored (MQS 0–8) by immunohistochemistry for p14ARF, p53 and Hdm2 expression in the nucleus and cytoplasm of invasive cancers and ductal carcinoma in situ (DCIS) are shown. Immunohistochemistry expression was assessed individually in the nucleus and the cytoplasm, and is defined as negative (0) (MQS 0–2), weak/moderate (1+) (MQS 3–5) and strong (2+) (MQS 6–8). Positivity for p14ARF, p53 and Hdm2 expression was defined as an MQS of 3 or more (1+/2+).